12:53 PM
Mar 14, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AYX1: Ph II ADYX-004 started

Adynxx began the double-blind, placebo-controlled, U.S. Phase II ADYX-004 trial to evaluate single intrathecal injections of 660 mg AYX1 given prior to intrathecal administration of spinal anesthetic...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >